

## Press Release

# Daiichi Sankyo Announces Rescheduling of the Announcement of Consolidated Financial Results for Year Ended March 31, 2026

**Tokyo, Japan - (April 24, 2026)** – Daiichi Sankyo Company, Limited (TSE: 4568; hereafter “the Company”) today announced that it has rescheduled the announcement of consolidated financial results for year ended March 31, 2026, originally scheduled for April 27, 2026.

### 1. Reasons for Change

The Company had been preparing to announce its financial results for the fiscal year ended March 31, 2026 on April 27, 2026; however, as additional time is required to finalize the financial figures, the Company has decided to change the announcement date.

The primary reason for the change is that the Company is currently reviewing the supply plans for its oncology products portfolio and development pipeline in light of rapidly changing business conditions. As a result, additional deliberation is required to reasonably estimate the amount of loss provisions to be recorded in connection with contracts with contract manufacturers.

In addition, regarding the announcement of the 5-year Business Plan (FY2026 – FY2030), scheduled for May 19, 2026, the Company has determined that presenting the financial results and the upcoming 5-year Business Plan together on the same date would be the most appropriate approach to enable investors and other participants in the financial markets to make informed investment decisions. Accordingly, the announcement of the 5-year Business Plan has been rescheduled to coincide with the financial results announcement.

### 2. Updated Announcement Schedule

Item	Previous Date	Updated Date
Consolidated Financial Results for Year Ended March 31, 2026	April 27, 2026	May 11, 2026
5-year Business Plan (FY26-FY30)	May 19, 2026	

### 3. Impact on Financial Results

The Company is currently assessing the impact of the above matters on its financial results for the fiscal year ended March 31, 2026. Should any matters requiring disclosure arise, the Company will promptly make an announcement.

The Company sincerely apologizes for any inconvenience and concern this may cause to its shareholders, investors, members of the press, and all other stakeholders, and kindly requests their continued understanding and support.

## **About Daiichi Sankyo**

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit [www.daiichisankyo.com](http://www.daiichisankyo.com).

### **Contacts:**

#### **Media Contact (Japan):**

Daiichi Sankyo Co., Ltd.

[DS-PR\\_jp@daiichisankyo.com](mailto:DS-PR_jp@daiichisankyo.com)

#### **Investor Relations Contact:**

[DaiichiSankyoIR\\_jp@daiichisankyo.com](mailto:DaiichiSankyoIR_jp@daiichisankyo.com)